摘要
Pancreatic ductal adenocarcinoma(PDAC)is a sneaky and lethal disease burdened by poor prognosis.PDAC is often detected too late to be successfully cured,and it has been estimated that it will be a leading cause of cancer-related deaths in the near future.During the last decade,multimodal treatments involving surgery,chemotherapy and radiotherapy have contributed to improving the prognosis of this disease;however,long-term results are still not satisfactory.Postoperative morbidity and mortality rates remain high,and systemic treatments are burdened by toxicity in both neoadjuvant and adjuvant settings.Advancements in technologies,targeted therapies,immunotherapy and PDAC microenvironment modulation strategies may represent useful potential weapons in the future.Nevertheless,in the fight against this dreadful disease,there is an urgent need for new,cheap and user-friendly tools for early detection.In this field,promising results have been found in nanotechnologies and“omics”analyses that search for new biomarkers to be used in primary and secondary prevention.However,there are many issues that need to be solved before considering these tools in daily clinical practice.This editorial reported the state of the art of pancreatic cancer management.
